Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Preferred Stock Liabilities (2020 - 2025)

Marimed (MRMD) has disclosed Preferred Stock Liabilities for 6 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • Quarterly Preferred Stock Liabilities fell 22.5% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Dec 2025, down 22.5% year-over-year, with the annual reading at $14.7 million for FY2025, 22.5% down from the prior year.
  • Preferred Stock Liabilities for Q4 2025 was $14.7 million at Marimed, roughly flat from $14.7 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $37.7 million in Q1 2021, with the low at $14.7 million in Q1 2025.
  • Average Preferred Stock Liabilities over 5 years is $26.7 million, with a median of $20.5 million recorded in 2023.
  • The sharpest move saw Preferred Stock Liabilities soared 156.2% in 2021, then plummeted 49.64% in 2023.
  • Over 5 years, Preferred Stock Liabilities stood at $37.7 million in 2021, then changed by 0.0% to $37.7 million in 2022, then tumbled by 49.64% to $19.0 million in 2023, then changed by 0.0% to $19.0 million in 2024, then fell by 22.5% to $14.7 million in 2025.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $14.7 million, $14.7 million, and $14.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.